10 Best New Stocks to Buy With Huge Upside Potential

Ed Yardeni of Yarden Research told CNBC’s “Squawk Box” that a June “swoon” after stronger-than-expected payrolls may have been limited to June 5, and he expects further upside in July. He cited SpaceX’s IPO as a positive sentiment signal and said S&P 500 firms are projected to grow earnings ~20% over seven quarters. The article also lists new stocks with claimed upside, including Caris Life Sciences’ $100m buyback authorization and Atour’s Q1 2026 revenue of RMB2.8b (+47.5% YoY).

Original reporting
Published Jun 16, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
10 Best New Stocks to Buy With Huge Upside Potential — source image
Decision brief

The 30-second read

$CAIBullishLow
01

Why it matters

For CAI and ATAT, the actionable content is limited to previously disclosed board authorization (CAI) and reported quarterly results (ATAT). The rest is macro/market commentary that does not introduce new, company-specific catalysts.

02

Market read

Traders get a recap of two company-specific datapoints (buyback authorization; quarterly growth/expansion), but the article does not provide fresh guidance, filings, or same-day catalysts.

03

What to watch

For CAI, execution details (timing/price) and any concurrent financing needs matter; for ATAT, RevPAR/occupancy and margin sustainability are key, and the article omits guidance/forward commentary.

Relevance 4/10Novelty 3/10Timing: Not time-specific beyond referencing June 8/May 13 results and a June 15 interview

Background

The piece is a promotional “10 best new stocks” list, anchored by an interview with Ed Yardeni on market momentum and earnings strength.

Company-level read

Ticker impact

$CAIBullishMedium confidence
Context

Caris Life Sciences authorized a $100M share repurchase program on June 8, giving a concrete capital-return catalyst for CAI.

Expected impact

Near-term bias modestly positive; follow-through depends on execution pace and stock reaction to the June 8 authorization.

Evidence & confidence

The article discloses a specific board-authorized repurchase size and mechanics, which traders can map to potential support, though it’s not a guidance/earnings surprise.

$ATATBullishMedium confidence
Context

Atour Lifestyle reported Q1 2026 results with revenue up 47.5% YoY and EBITDA growth, plus continued hotel expansion.

Expected impact

Potentially positive near-term sentiment; magnitude depends on how the market interprets profitability and unit economics.

Evidence & confidence

The article provides multiple hard financial/operational datapoints from the quarter, but it’s framed as a listicle rather than a fresh same-day catalyst.

Market effects

Highlights capital-return (buybacks) and growth/expansion narratives in healthcare/precision medicine and hospitality, but without sector-wide new data.

ATAT’s results are China-exposed; sentiment could be influenced by broader China consumer/hospitality demand expectations, though no new macro datapoint is provided.

Mentions SpaceX/AI sentiment broadly, but provides no direct global market mechanism tied to CAI or ATAT.

Counterpoint

Listicle framing may overstate “huge upside”; buyback authorization and prior-quarter results may already be priced, limiting incremental edge.

Key entities

  • Caris Life Sciences Inc.

    Board authorized up to $100M common stock repurchases (June 8).

  • Atour Lifestyle Holdings Limited

    Reported Q1 2026 results with revenue and profitability growth and continued hotel expansion (reported May 13).

  • Ed Yardeni

    Yarden Research president quoted on market momentum and earnings-led upside.

Related articles

Med

Atour Lifestyle Holdings Ltd (ATAT) (Q3 2026) Earnings Call Highlights: Revenue Surges

Atour Lifestyle (ATAT) reported Q3 2026 revenue growth of 30.5% to RMB3.4B. Adjusted net profit rose 26.2% to RMB615M. The company raised 2026 retail revenue growth forecast to 50-55% YOY. CEO Wang Haijun expressed confidence in hotel expansion and domestic industry trends. Q3 saw 128 new hotel openings, bringing total to 2,288. Retail revenue grew 51% YOY to RMB1.36B, driven by product successes.

$ATATMed

What Atour Lifestyle (ATAT) Said on Its Q3 Earnings Call

Atour Lifestyle (ATAT) reported Q3 managed hotel revenue up 20.4% to CNY 1.9B, while leased hotel revenue fell 18.6% to CNY 134M. Hotel gross margin improved to 37.9%. The company plans a new upscale hotel brand and has 124M registered members. It declared a $59M dividend and repurchased over $120M in shares. ATAT targets 100% of prior year's net income for shareholder returns.